Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Andreeff

Showing results (321-330 of 504) with videos related to

Pageof 51
Sort By:
Journal of the National Cancer Institute|February 15, 2014
Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agentsBing Z Carter, Po Yee Mak, Duncan H Mak, et al.
Stem Cells (Dayton, Ohio)|May 14, 2015
Mesenchymal Stem Cells Isolated From Human Gliomas Increase Proliferation and Maintain Stemness of Glioma Stem Cells Through the IL-6/gp130/STAT3 PathwayAnwar Hossain, Joy Gumin, Feng Gao, et al.
Blood|June 3, 2015
Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapyByung-Sik Cho, Zhihong Zeng, Hong Mu, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 20, 2011
Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenibManish Sharma, Farhad Ravandi, Ulas Darda Bayraktar, et al.
American Journal of Hematology|July 23, 2020
Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patientsGautam Borthakur, Zhihong Zeng, Jorge E Cortes, et al.
Leukemia|August 8, 2022
A phase two study of high dose blinatumomab in Richter's syndromePhilip A Thompson, Xianli Jiang, Pinaki Banerjee, et al.
Blood|February 2, 2017
FZR1 loss increases sensitivity to DNA damage and consequently promotes murine and human B-cell acute leukemiaJo Ishizawa, Eiji Sugihara, Shinji Kuninaka, et al.
Blood|April 9, 2013
Prognostic impact and targeting of CRM1 in acute myeloid leukemiaKensuke Kojima, Steven M Kornblau, Vivian Ruvolo, et al.
Blood Cancer Journal|April 23, 2023
Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimeticsBing Z Carter, Po Yee Mak, Wenjing Tao, et al.
Blood Cancer Journal|May 16, 2023
Correction: Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimeticsBing Z Carter, Po Yee Mak, Wenjing Tao, et al.
Pageof 51

Showing results (321-330 of 504) with videos related to

Sort By:
Pageof 51
Journal of the National Cancer Institute|February 15, 2014
Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agentsBing Z Carter, Po Yee Mak, Duncan H Mak, et al.
Stem Cells (Dayton, Ohio)|May 14, 2015
Mesenchymal Stem Cells Isolated From Human Gliomas Increase Proliferation and Maintain Stemness of Glioma Stem Cells Through the IL-6/gp130/STAT3 PathwayAnwar Hossain, Joy Gumin, Feng Gao, et al.
Blood|June 3, 2015
Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapyByung-Sik Cho, Zhihong Zeng, Hong Mu, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 20, 2011
Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenibManish Sharma, Farhad Ravandi, Ulas Darda Bayraktar, et al.
American Journal of Hematology|July 23, 2020
Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patientsGautam Borthakur, Zhihong Zeng, Jorge E Cortes, et al.
Leukemia|August 8, 2022
A phase two study of high dose blinatumomab in Richter's syndromePhilip A Thompson, Xianli Jiang, Pinaki Banerjee, et al.
Blood|February 2, 2017
FZR1 loss increases sensitivity to DNA damage and consequently promotes murine and human B-cell acute leukemiaJo Ishizawa, Eiji Sugihara, Shinji Kuninaka, et al.
Blood|April 9, 2013
Prognostic impact and targeting of CRM1 in acute myeloid leukemiaKensuke Kojima, Steven M Kornblau, Vivian Ruvolo, et al.
Blood Cancer Journal|April 23, 2023
Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimeticsBing Z Carter, Po Yee Mak, Wenjing Tao, et al.
Blood Cancer Journal|May 16, 2023
Correction: Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimeticsBing Z Carter, Po Yee Mak, Wenjing Tao, et al.
Pageof 51